DE69210067D1 - Hydraxamsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung - Google Patents

Hydraxamsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung

Info

Publication number
DE69210067D1
DE69210067D1 DE69210067T DE69210067T DE69210067D1 DE 69210067 D1 DE69210067 D1 DE 69210067D1 DE 69210067 T DE69210067 T DE 69210067T DE 69210067 T DE69210067 T DE 69210067T DE 69210067 D1 DE69210067 D1 DE 69210067D1
Authority
DE
Germany
Prior art keywords
hydraxamic
preparation
acid derivatives
derivatives
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69210067T
Other languages
English (en)
Other versions
DE69210067T2 (de
Inventor
Raymond Paul Beckett
Michael John Crimmin
Alan Horsby Davidson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
British Biotech Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Biotech Pharmaceuticals Ltd filed Critical British Biotech Pharmaceuticals Ltd
Publication of DE69210067D1 publication Critical patent/DE69210067D1/de
Application granted granted Critical
Publication of DE69210067T2 publication Critical patent/DE69210067T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69210067T 1991-02-07 1992-02-07 Hydraxamsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung Expired - Fee Related DE69210067T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919102635A GB9102635D0 (en) 1991-02-07 1991-02-07 Compounds

Publications (2)

Publication Number Publication Date
DE69210067D1 true DE69210067D1 (de) 1996-05-30
DE69210067T2 DE69210067T2 (de) 1996-11-14

Family

ID=10689687

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69210067T Expired - Fee Related DE69210067T2 (de) 1991-02-07 1992-02-07 Hydraxamsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung

Country Status (11)

Country Link
US (2) US5300674A (de)
EP (1) EP0498665B1 (de)
JP (1) JPH06506445A (de)
AU (1) AU1194492A (de)
CA (1) CA2100661A1 (de)
DE (1) DE69210067T2 (de)
GB (1) GB9102635D0 (de)
IE (1) IE920404A1 (de)
NZ (1) NZ241558A (de)
WO (1) WO1992013831A1 (de)
ZA (1) ZA92908B (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
US5530161A (en) * 1991-07-08 1996-06-25 British Bio-Technology Limited Hydroxamic acid based collagenase inhibitors
DE69309047T2 (de) * 1992-04-07 1997-09-11 British Biotech Pharm Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9220845D0 (en) * 1992-10-03 1992-11-18 British Bio Technology Vasoactive peptide inhibition
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
CA2158352A1 (en) * 1993-03-16 1994-09-29 Michael John Crimmin Hydroxamic acid derivatives as metalloproteinase inhibitors
US5734204A (en) * 1993-03-17 1998-03-31 Canon Kabushiki Kaisha Backup apparatus
CA2170158A1 (en) * 1993-08-23 1995-03-02 Roy A. Black Inhibitors of tnf-alpha secretion
US5594106A (en) * 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
CN1049651C (zh) * 1994-01-20 2000-02-23 英国生物技术药物有限公司 金属蛋白酶抑制剂
GB9401129D0 (en) * 1994-01-21 1994-03-16 British Bio Technology Hydroxamic acid derivatives as metalloproteinase inhibitors
DE69529100T2 (de) * 1994-01-22 2003-07-17 British Biotech Pharm Metalloproteinaseinhibitoren
GB9404046D0 (en) * 1994-03-03 1994-04-20 Smithkline Beecham Corp Novel compounds
US5665753A (en) * 1994-03-03 1997-09-09 Smithkline Beecham Corporation Cytokine inhibiting imidazole substituted hydroxamic acid derivatives
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5639746A (en) * 1994-12-29 1997-06-17 The Procter & Gamble Company Hydroxamic acid-containing inhibitors of matrix metalloproteases
US5919940A (en) * 1995-01-20 1999-07-06 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
GB9504084D0 (en) * 1995-03-01 1995-04-19 British Biotech Pharm Synthesis of carboxylic and hydroxamic acid derivatives
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
US5691381A (en) * 1995-04-18 1997-11-25 The Dupont Merck Pharmaceutical Company Hydroxamic and carbocyclic acids as metalloprotease inhibitors
DE69632821T2 (de) * 1995-04-25 2005-08-25 Daiichi Fine Chemical Co., Ltd., Takaoka In wasser hochlöslicher metalloproteinase-inhibitor
AU5347896A (en) * 1995-04-26 1996-11-18 Sankyo Company Limited Beta-nonylhydroxamic acid derivatives
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
PL326714A1 (en) * 1995-11-14 1998-10-26 Du Pont Merck Pharma Novel macrocyclic compounds as inhibitors of metaloproteinases
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
US6281352B1 (en) 1995-11-14 2001-08-28 Dupont Pharmaceuticals Company Macrocyclic compounds as metalloprotease inhibitors
WO1997019053A1 (en) 1995-11-23 1997-05-29 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
NZ334257A (en) * 1996-08-28 2000-11-24 Procter & Gamble Spirocyclic metalloprotease inhibitors
TR199900382T2 (xx) * 1996-08-28 1999-05-21 The Procter & Gamble Company Heterosiklik metaloproteaz inhibit�rleri.
ATE227274T1 (de) * 1996-08-28 2002-11-15 Procter & Gamble 1,3-diheterozyklische metalloprotease inhibitoren
NZ334252A (en) * 1996-08-28 2000-11-24 Procter & Gamble Heterocyclic metalloprotease inhibitors
JP3539736B2 (ja) * 1996-08-28 2004-07-07 ザ プロクター アンド ギャンブル カンパニー 基質メタロプロテアーゼインヒビターとしてのホスフィン酸アミド
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
ATE220660T1 (de) 1996-09-10 2002-08-15 British Biotech Pharm Cytostatische hydroxamsäurederivate
US7883872B2 (en) 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
JPH10130217A (ja) * 1996-11-01 1998-05-19 Kotobuki Seiyaku Kk カルボン酸及びその誘導体及びその製造法並びにこれを含有する医薬組成物
ZA9820B (en) * 1997-01-07 1998-07-02 Abbott Lab Macrocyclic inhibitors of matrix metalloproteinases and tnf x secretion
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
ZA9818B (en) * 1997-01-07 1998-07-02 Abbott Lab C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion
IL131543A (en) * 1997-02-25 2005-08-31 Univ Michigan Cosmetic methods and compositions for preventing and treating chronological aging in human skin
NZ503945A (en) 1997-07-31 2002-11-26 Procter & Gamble Metalloprotease-inhibiting amide derivatives
HRP980443A2 (en) 1997-08-18 1999-10-31 Carl P. Decicco Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
DE69922978T2 (de) 1998-10-06 2005-12-08 Emalfarb, Mark Aaron, Jupiter Transformationsystem in filamentösen fungiziden chrysosporium-wirtszellen
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
EP1165530A2 (de) 1999-03-03 2002-01-02 The Procter & Gamble Company Dihetero-substituierte metalloprotease-inhibitoren
AU764051B2 (en) 1999-03-03 2003-08-07 Procter & Gamble Company, The Alkenyl- and alkynyl-containing metalloprotease inhibitors
US6696456B1 (en) * 1999-10-14 2004-02-24 The Procter & Gamble Company Beta disubstituted metalloprotease inhibitors
GB9925264D0 (en) * 1999-10-26 1999-12-29 Zeneca Ltd Chemical compounds
SK12842002A3 (sk) 2000-03-21 2003-02-04 The Procter And Gamble Company Heterocyklický vedľajší reťazec obsahujúci N-substituované inhibítory metaloproteáz a farmaceutický prípravok s ich obsahom
RU2002128003A (ru) * 2000-03-21 2004-02-27 Дзе Проктер Энд Гэмбл Компани (US) Ингибиторы металлопротеаз, содержащие карбоциклическую боковую цепь
JP2003528082A (ja) * 2000-03-21 2003-09-24 ザ プロクター アンド ギャンブル カンパニー ニフッ化酪酸メタロプロテアーゼ阻害物質
AU2001271068A1 (en) * 2000-07-18 2002-01-30 Chugai Seiyaku Kabushiki Kaisha Matrix metalloprotease inhibitors
EP1306367B1 (de) 2000-07-19 2007-07-18 Mitsubishi Pharma Corporation Sulphonsäurederivate von hydroxamsäuren und deren verwendung in medizinischen produkten
ES2283589T3 (es) 2001-06-15 2007-11-01 Vicuron Pharmaceuticals, Inc. Compuestos biciclicos de pirrolidina.
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US20040192658A1 (en) * 2002-12-27 2004-09-30 Angiotech International Ag Compositions and methods of using collajolie
US7846963B2 (en) 2003-05-17 2010-12-07 Korea Research Institute Of Bioscience And Biotechnology 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same
WO2006128006A1 (en) 2005-05-26 2006-11-30 The Regents Of The University Of Colorado Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
US8551751B2 (en) 2007-09-07 2013-10-08 Dyadic International, Inc. BX11 enzymes having xylosidase activity
EP2453906A4 (de) 2009-07-02 2014-01-15 Musc Found For Res Dev Verfahren zur stimulation der leberregeneration
CN103435514B (zh) * 2013-08-01 2015-11-25 中国人民解放军军事医学科学院毒物药物研究所 基质金属蛋白酶抑制剂及其用途
CN106946792B (zh) * 2017-03-29 2019-07-26 深圳市坤健创新药物研究院 一种酞嗪酮的异羟肟酸衍生物及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105789A (en) * 1976-05-10 1978-08-08 E. R. Squibb & Sons, Inc. Carboxyalkylacylamino acids
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4496540A (en) * 1982-12-30 1985-01-29 Biomeasure, Inc. Therapeutic compounds
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8827308D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds

Also Published As

Publication number Publication date
JPH06506445A (ja) 1994-07-21
NZ241558A (en) 1994-08-26
US5412145A (en) 1995-05-02
IE920404A1 (en) 1992-08-12
AU1194492A (en) 1992-09-07
WO1992013831A1 (en) 1992-08-20
EP0498665A1 (de) 1992-08-12
US5300674A (en) 1994-04-05
CA2100661A1 (en) 1992-08-08
DE69210067T2 (de) 1996-11-14
EP0498665B1 (de) 1996-04-24
ZA92908B (en) 1993-08-09
GB9102635D0 (en) 1991-03-27

Similar Documents

Publication Publication Date Title
DE69210067D1 (de) Hydraxamsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
DE69211076T3 (de) Polyasparaginsäure-zusammensetzung, verfahren zu ihrer herstellung und ihre verwendung
DE58909834D1 (de) Phthalimidoperoxihexansäure, Verfahren zu deren Herstellung und deren Verwendung
DE59307218D1 (de) Modifizierte polyasparaginsäuren, verfahren zu ihrer herstellung und ihre verwendung
DE59208394D1 (de) Diallylammonium-Verbindungen, Verfahren zu ihrer Herstellung sowie ihre Verwendung
DE58908176D1 (de) Chinacridon-Pigmente, Verfahren zu ihrer Herstellung und ihre Verwendung.
DE59207620D1 (de) NIR-Farbstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung
PT78757B (de) Tetrahydropyridazinonderivate verfahren zu ihrer herstellung und ihre verwendung
DE69131807D1 (de) Propensäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Fungizide
PT84460A (de) 1,1-disubstituierte cyclopropanderivate verfahren zu ihrer herstellung und ihre verwendung
ATA198791A (de) Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
ATE172196T1 (de) 2- (2-alkoxy-6-trifluormethylpyrimidin-4-yl)- oxymethylen>-phenylessigsäurederivate, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung
DE69108356D1 (de) Hydrazonderivate, Verfahren zu ihrer Herstellung und ihre Verwendung.
DE69204806D1 (de) 1-Cyanomethyl-4-carboxymethyl-3-ketopiperazine, ihre Salze und Verfahren zu ihrer Herstellung.
DE69225625T2 (de) Carbaminsäurederivate und Verfahren zu ihrer Herstellung
DE3889637D1 (de) Monoazopigmente, Verfahren zu ihrer Herstellung und ihre Verwendung.
DE59608892D1 (de) Iminooxyphenylessigsäurederivate, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung
DE69118850D1 (de) Derivate der 1,4-Benzothiazin-2-essigsäure, Verfahren zu ihrer Herstellung und ihre Verwendung
DE3682370D1 (de) 3-aminocarbonyl-1,4-dihydropyridin-5-carboxylsaeurederivate, verfahren zu ihrer herstellung, ihre verwendung und diese enthaltende pharmazeutische zusammensetzungen.
DE59108884D1 (de) Triphendioxazinverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung
DE59800568D1 (de) Benzoxazindionderivate, Verfahren zu ihrer Herstellung und ihre Verwendung
DE69732570D1 (de) Sulfonsäureester-derivate, verfahren zu ihrer herstellung und ihre verwendung
DE69107143D1 (de) 2,2,3-Trimethylcyclopentenylaceton-Derivate, ihre organoleptische Verwendung und Verfahren zu ihrer Herstellung.
DE69127797D1 (de) Acylaminopyridincarboxamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Fungizide
DE69206940D1 (de) 2-Pyridon-2-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Fungizide

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee